RxSight (RXST) Competitors $7.80 +0.02 (+0.26%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.81 +0.01 (+0.12%) As of 08/1/2025 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXST vs. PLSE, BLFS, TNDM, MDXG, INMD, KMTS, IRMD, SIBN, BBNX, and EMBCShould you be buying RxSight stock or one of its competitors? The main competitors of RxSight include Pulse Biosciences (PLSE), BioLife Solutions (BLFS), Tandem Diabetes Care (TNDM), MiMedx Group (MDXG), InMode (INMD), Kestra Medical Technologies (KMTS), iRadimed (IRMD), SiBone (SIBN), Beta Bionics (BBNX), and Embecta (EMBC). These companies are all part of the "medical equipment" industry. RxSight vs. Its Competitors Pulse Biosciences BioLife Solutions Tandem Diabetes Care MiMedx Group InMode Kestra Medical Technologies iRadimed SiBone Beta Bionics Embecta Pulse Biosciences (NASDAQ:PLSE) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation. Which has more risk & volatility, PLSE or RXST? Pulse Biosciences has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, RxSight has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Is PLSE or RXST more profitable? Pulse Biosciences has a net margin of 0.00% compared to RxSight's net margin of -17.90%. RxSight's return on equity of -9.54% beat Pulse Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Pulse BiosciencesN/A -68.44% -58.17% RxSight -17.90%-9.54%-8.51% Do analysts rate PLSE or RXST? Pulse Biosciences presently has a consensus target price of $22.00, indicating a potential upside of 49.15%. RxSight has a consensus target price of $17.50, indicating a potential upside of 124.36%. Given RxSight's higher probable upside, analysts plainly believe RxSight is more favorable than Pulse Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulse Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00RxSight 2 Sell rating(s) 8 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.91 Which has stronger earnings and valuation, PLSE or RXST? RxSight has higher revenue and earnings than Pulse Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPulse Biosciences$700K1,417.48-$53.58MN/AN/ARxSight$139.93M2.27-$27.45M-$0.67-11.64 Do institutionals and insiders have more ownership in PLSE or RXST? 77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 71.5% of Pulse Biosciences shares are held by company insiders. Comparatively, 9.6% of RxSight shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor PLSE or RXST? In the previous week, RxSight had 35 more articles in the media than Pulse Biosciences. MarketBeat recorded 38 mentions for RxSight and 3 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.50 beat RxSight's score of 0.05 indicating that Pulse Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 2 Very Positive mention(s) 0 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryRxSight beats Pulse Biosciences on 7 of the 13 factors compared between the two stocks. Get RxSight News Delivered to You Automatically Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXST vs. The Competition Export to ExcelMetricRxSightMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$316.16M$6.70B$5.48B$9.54BDividend YieldN/A1.32%4.73%4.09%P/E Ratio-11.6420.9428.8623.83Price / Sales2.2754.12371.7266.14Price / CashN/A20.5035.4557.96Price / Book1.124.468.275.54Net Income-$27.45M$174.54M$3.25B$259.28M7 Day Performance-2.13%-5.27%-3.73%-4.68%1 Month Performance-40.64%-3.94%4.29%4.36%1 Year Performance-81.33%8.26%25.87%17.89% RxSight Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXSTRxSight3.3687 of 5 stars$7.80+0.3%$17.50+124.4%-82.4%$316.16M$139.93M-11.64220Trending NewsUpcoming EarningsPLSEPulse Biosciences3.9326 of 5 stars$14.97-0.9%$22.00+47.0%-2.3%$1.02B$700K0.00140News CoveragePositive NewsBLFSBioLife Solutions2.8081 of 5 stars$20.76-0.3%$31.17+50.1%-10.9%$996.41M$82.25M-71.58440Upcoming EarningsGap DownTNDMTandem Diabetes Care3.5041 of 5 stars$14.63-0.9%$32.71+123.6%-56.3%$983.79M$940.20M-5.262,650Positive NewsUpcoming EarningsMDXGMiMedx Group3.0984 of 5 stars$6.65+3.6%$11.50+72.9%+7.2%$948.25M$348.88M24.63870Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionINMDInMode3.1204 of 5 stars$13.96+0.4%$18.54+32.8%-17.1%$878.29M$394.82M8.85480News CoverageEarnings ReportAnalyst ForecastKMTSKestra Medical Technologies0.9984 of 5 stars$16.63+4.6%$27.33+64.4%N/A$816.44M$59.81M0.00300Positive NewsIRMDiRadimed4.1836 of 5 stars$56.19-0.9%$72.00+28.1%+43.4%$720.82M$73.24M36.25110Trending NewsDividend AnnouncementGap UpSIBNSiBone3.6999 of 5 stars$16.67+0.3%$22.50+35.0%+17.2%$708.25M$167.18M-26.05350Upcoming EarningsBBNXBeta Bionics2.3305 of 5 stars$14.30+5.2%$23.44+63.9%N/A$589.21M$65.12M0.00294Trending NewsEarnings ReportAnalyst ForecastLockup ExpirationAnalyst RevisionEMBCEmbecta4.6601 of 5 stars$10.29+5.2%$19.00+84.6%-35.3%$571.57M$1.12B11.432,100News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies Pulse Biosciences Alternatives BioLife Solutions Alternatives Tandem Diabetes Care Alternatives MiMedx Group Alternatives InMode Alternatives Kestra Medical Technologies Alternatives iRadimed Alternatives SiBone Alternatives Beta Bionics Alternatives Embecta Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXST) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
